Skip to main content
. 2011 Dec 27;14(4):262–268. doi: 10.4048/jbc.2011.14.4.262

Figure 2.

Figure 2

Five-year relapse-free survival according to Annexin A1 (ANXA1) expression with clinical variables. ANXA1 positive groups have poor relapse-free survivals in node-positive patients (A), in HER2-positive patients (B), and in non-triple negative breast cancer patients (C).